Microbot Medical Inc. (MBOT)
Automate Your Wheel Strategy on MBOT
With Tiblio's Option Bot, you can configure your own wheel strategy including MBOT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MBOT
- Rev/Share 0.0023
- Book/Share 0.832
- PB 3.666
- Debt/Equity 0.0049
- CurrentRatio 12.0612
- ROIC -0.4417
- MktCap 138989818.0
- FreeCF/Share -0.272
- PFCF -14.0026
- PE -8.7574
- Debt/Assets 0.0045
- DivYield 0
- ROE -0.7627
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
All You Need to Know About Microbot Medical (MBOT) Rating Upgrade to Buy
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Microbot Medical (MBOT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Microbot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds
Published: September 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
$25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment options $25.2 million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate gross proceeds upon the exercise in full of short-term preferred investment options
Read More
Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
MBOT shares rise as FDA clears its LIBERTY robotic system, paving the way for U.S. market entry and fueling strong investor momentum.
Read More
Microbot Shares Rise as New U.S. Patent Expands LIBERTY System Market
Published: August 21, 2025 by: Zacks Investment Research
Sentiment: Positive
MBOT's new U.S. patent boosts the LIBERTY system's flexibility, expanding its U.S. market reach to over six million annual procedures.
Read More
Microbot Medical (MBOT) Upgraded to Buy: What Does It Mean for the Stock?
Published: June 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Microbot Medical (MBOT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Microbot Medical Selected for Preliminary Inclusion to Russell Microcap® Index
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
HINGHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced that it has been selected for inclusion in the preliminary list of additions to the Russell Microcap® Index, as published by FTSE Russell on Friday, May 23, 2025. The newly reconstituted indexes are expected to take effect after U.S. market close on Friday, June 27, 2025, and be part of the 2025 Russell indexes reconstitution when the U.S. market opens on Monday, June 30, 2025.
Read More
About Microbot Medical Inc. (MBOT)
- IPO Date 1992-03-25
- Website https://www.microbotmedical.com
- Industry Medical - Instruments & Supplies
- CEO Harel Gadot
- Employees 20